InflaRx
Petra Eßer joined InflaRx in May 2021 as Head of Finance and Head Controller. She started her career at a Big Four accounting firm, then worked for various IT, Pharmaceutical, and Biotechnology companies before landing at InflaRx.
She received a Business Administration degree with a focus in Finance and Marketing from the University of Bayreuth.
This person is not in any offices
InflaRx
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a.